HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ED-Spiked Supplements Sold On Amazon Fill US FDA’s Recall Plate

Executive Summary

Announcements for seven adulterated male sexual enhancement products were published across the work week, concluding with NANA Collection LLC’s products branded PremierZen Platinum 5000, found with undisclosed tadalafil, and Triple SupremeZen 3500, found to contain tadalafil and sildenafil, on 2 April.

You may also be interested in...



US FDA Testing Finds Consumer Health Market Problems, But It Can’t Test Entire Marketplace

CDER compliance office director Donald Ashley offers a cautionary note to temper expectations for the FDA’s enforcement in the supplement sector. “We continue to warn the public about products very often sold as dietary supplements that contain hidden drugs,” he says.

Natural Alternatives International First To Clear NPA's, Retailers' Safety, Compliance Standards

Contract manufacturer showed compliance with Supplement Safety & Compliance Initiative standards to globally harmonize benchmarks for natul products. Retailers including Amazon and Walmart acknowledge SSCI as benchmarks companies must meet in order to sell products on their platforms.

Amazon Flexes E-Commerce Heft By Imposing Quality-Control Requirements For Supplements

Amazon requires firms selling supplements on its site in the US to demonstrate their products comply with FDA regulations for labeling and GMPs. Marketers that don’t submit documentation face removal of their products from the site.

Related Content

Topics

UsernamePublicRestriction

Register

RS151185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel